Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Ritz

Showing results (41-50 of 315) with videos related to

Pageof 32
Sort By:
American Journal of Hematology|August 30, 2008
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remissionRichard M Stone, Daniel J DeAngelo, Anna Janosova, et al.
The Journal of Clinical Investigation|February 16, 2026
The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkersMichael J Martens, Debjani Dutta, Yongzi Yu, et al.
Frontiers in Immunology|January 1, 2021
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic LeukemiaLina Driouk, Joanina K Gicobi, Yusuke Kamihara, et al.
Experimental Hematology|January 28, 2014
Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic targetShikiko Ueno, Jiayun Lu, Jie He, et al.
Frontiers in Immunology|October 3, 2022
Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host diseaseVeronica Donato, Haesook T Kim, Peter Stowe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cellsEmmanuel Zorn, Kathy S Wang, Ephraim P Hochberg, et al.
Journal of Pediatric Surgery|June 19, 2008
Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocolShaun A Steigman, Myriam Armant, Lucy Bayer-Zwirello, et al.
NEJM Evidence|June 25, 2024
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 DiabetesJason L Gaglia, Heather L Daley, Nora K Bryant, et al.
Blood|August 11, 2005
Evidence for ineffective erythropoiesis in severe sickle cell diseaseCatherine J Wu, Lakshamanan Krishnamurti, Jeffery L Kutok, et al.
Medrxiv : the Preprint Server for Health Sciences|March 27, 2026
Cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell LymphomaConor Loy, Glory Agun, Katie Maurer, et al.
Pageof 32

Showing results (41-50 of 315) with videos related to

Sort By:
Pageof 32
American Journal of Hematology|August 30, 2008
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remissionRichard M Stone, Daniel J DeAngelo, Anna Janosova, et al.
The Journal of Clinical Investigation|February 16, 2026
The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkersMichael J Martens, Debjani Dutta, Yongzi Yu, et al.
Frontiers in Immunology|January 1, 2021
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic LeukemiaLina Driouk, Joanina K Gicobi, Yusuke Kamihara, et al.
Experimental Hematology|January 28, 2014
Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic targetShikiko Ueno, Jiayun Lu, Jie He, et al.
Frontiers in Immunology|October 3, 2022
Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host diseaseVeronica Donato, Haesook T Kim, Peter Stowe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cellsEmmanuel Zorn, Kathy S Wang, Ephraim P Hochberg, et al.
Journal of Pediatric Surgery|June 19, 2008
Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocolShaun A Steigman, Myriam Armant, Lucy Bayer-Zwirello, et al.
NEJM Evidence|June 25, 2024
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 DiabetesJason L Gaglia, Heather L Daley, Nora K Bryant, et al.
Blood|August 11, 2005
Evidence for ineffective erythropoiesis in severe sickle cell diseaseCatherine J Wu, Lakshamanan Krishnamurti, Jeffery L Kutok, et al.
Medrxiv : the Preprint Server for Health Sciences|March 27, 2026
Cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell LymphomaConor Loy, Glory Agun, Katie Maurer, et al.
Pageof 32